Provided by Tiger Fintech (Singapore) Pte. Ltd.

Dyne Therapeutics, Inc.

7.85
+0.38005.09%
Post-market: 7.79-0.0600-0.76%16:29 EDT
Volume:1.45M
Turnover:11.34M
Market Cap:888.00M
PE:-2.33
High:8.01
Open:7.42
Low:7.42
Close:7.47
1D
5D
D
W
M
Q
Y
1m
5m
10m
15m
30m
1h
2h
More
1D
5D
D
W
M
Q
Y
1m
5m
10m
15m
30m
1h
2h

Dyne Therapeutics, Inc. (DYN): Among the Best Rebound Stocks to Invest In Now

Insider Monkey
·
06 Feb

Zacks Industry Outlook Highlights Corcept, Amneal, Dyne, Nektar and Cardiol

Zacks
·
03 Feb

5 Small Drug Stocks to Add to Your Kitty in the Trump 2.0 Era

Zacks
·
31 Jan

Down -42.2% in 4 Weeks, Here's Why Dyne Therapeutics (DYN) Looks Ripe for a Turnaround

Zacks
·
28 Jan

Dyne Therapeutics Gains ‘Buy’ Rating Following FDA Fast Track Designation and Promising Trial Results

TIPRANKS
·
22 Jan

Dyne Therapeutics Says US FDA Grants Fast Track tag to Neuromuscular Disease Therapy

MT Newswires Live
·
21 Jan

Dyne Gets FDA Fast-Track Status for Neuromuscular Product Candidate

Dow Jones
·
21 Jan

BRIEF-Dyne Therapeutics Receives FDA Fast Track Designation For Dyne-101

Reuters
·
21 Jan

Dyne Therapeutics receives FDA Fast Track designation for DYNE-101

TIPRANKS
·
21 Jan

Dyne Therapeutics Inc - to Submit for U.S. Accelerated Approval in H1 2026

THOMSON REUTERS
·
21 Jan

Dyne Therapeutics Receives FDA Fast Track Designation for Dyne-101 for the Treatment of Myotonic Dystrophy Type 1

THOMSON REUTERS
·
21 Jan

Dyne Therapeutics Price Target Maintained With a $45.00/Share by RBC Capital

Dow Jones
·
14 Jan

Positive Outlook for Dyne Therapeutics as DYN-101 Shows Promising Clinical Results and Strategic Regulatory Advancements

TIPRANKS
·
11 Jan

Dyne Therapeutics: Positive Phase 1/2 Trial Results for DYNE-101 Lead to Buy Rating and Overweight Stock Recommendation

TIPRANKS
·
11 Jan

Small U.S. Stocks Close Lower; Dyne Therapeutics Posts Biggest Loss

Dow Jones
·
10 Jan

Dyne Therapeutics’ Promising Data and Strategic Moves Drive Buy Rating by Andrew Fein

TIPRANKS
·
10 Jan

H.C. Wainwright keeps Buy on Dyne Therapeutics after data

TIPRANKS
·
10 Jan

RBC remain buyers of Dyne Therapeutics after DM1 and DMD data

TIPRANKS
·
10 Jan

Dyne Therapeutics' Muscle Dystrophy Treatment Demonstrates DMPK Reduction, Splicing Correction; Shares Fall

MT Newswires Live
·
10 Jan

Dyne Therapeutics Inc - Plans U.S. Accelerated Approval Submission for Dyne-101 in H1 2026

THOMSON REUTERS
·
10 Jan

If the download button clicks without skipping, click on the top right menu and select "Open in Browser."